1. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Issue 1 (January 2017) Authors: Hellmann, Matthew D; Rizvi, Naiyer A; Goldman, Jonathan W; Gettinger, Scott N; Borghaei, Hossein; Brahmer, Julie R; Ready, Neal E; Gerber, David E; Chow, Laura Q; Juergens, Rosalyn A; Shepherd, Frances A; Laurie, Scott A; Geese, William J; Agrawal, Shruti; Young, Tina C; Li, Xuemei; Antonia, Scott J Journal: Lancet oncology Issue: Volume 18:Issue 1(2017:Jan.) Page Start: 31 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗